• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Gram-negative Bacteria With Difficult-to-Treat Resistance: A Moving Target.

作者信息

Al-Hasan Majdi N

机构信息

Department of Internal Medicine, University of South Carolina School of Medicine, Columbia, South Carolina, USA.

Prisma Health-Midlands, Columbia, South Carolina, USA.

出版信息

Clin Infect Dis. 2021 Jun 15;72(12):2121-2123. doi: 10.1093/cid/ciaa384.

DOI:10.1093/cid/ciaa384
PMID:32249916
Abstract
摘要

相似文献

1
Gram-negative Bacteria With Difficult-to-Treat Resistance: A Moving Target.具有难以治疗的耐药性的革兰氏阴性菌：一个不断变化的目标。
Clin Infect Dis. 2021 Jun 15;72(12):2121-2123. doi: 10.1093/cid/ciaa384.
2
Activity of Imipenem-Relebactam and Ceftolozane-Tazobactam against Resistant Gram-Negative Bacilli.亚胺培南-雷巴他定和头孢他啶-他唑巴坦对耐药革兰氏阴性杆菌的活性。
Antimicrob Agents Chemother. 2018 Jul 27;62(8). doi: 10.1128/AAC.00533-18. Print 2018 Aug.
3
In Vitro Activity of Imipenem/Relebactam and Ceftolozane/Tazobactam Against Clinical Isolates of Gram-negative Bacilli With Difficult-to-Treat Resistance and Multidrug-resistant Phenotypes-Study for Monitoring Antimicrobial Resistance Trends, United States 2015-2017.亚胺培南/瑞来巴坦和头孢洛扎/他唑巴坦对具有难治性耐药和多重耐药表型的革兰氏阴性杆菌临床分离株的体外活性——美国2015 - 2017年抗菌药物耐药趋势监测研究
Clin Infect Dis. 2021 Jun 15;72(12):2112-2120. doi: 10.1093/cid/ciaa381.
4
Susceptibility of Ceftolozane-Tazobactam and Ceftazidime-Avibactam Against a Collection of β-Lactam-Resistant Gram-Negative Bacteria.头孢洛扎坦-他唑巴坦和头孢他啶-阿维巴坦对一组耐β-内酰胺革兰氏阴性菌的敏感性
Ann Lab Med. 2017 Mar;37(2):174-176. doi: 10.3343/alm.2017.37.2.174.
5
Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.头孢地尔：一种具有抗碳青霉烯类和多药耐药革兰氏阴性杆菌活性的铁载体头孢菌素。
Drugs. 2019 Feb;79(3):271-289. doi: 10.1007/s40265-019-1055-2.
6
Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections.头孢洛扎他唑巴坦和头孢他啶/阿维巴坦：两种新型β-内酰胺/β-内酰胺酶抑制剂复方制剂，用于治疗耐药革兰氏阴性菌感染。
Int J Antimicrob Agents. 2015 Sep;46(3):266-71. doi: 10.1016/j.ijantimicag.2015.05.003. Epub 2015 Jun 14.
7
Defining the Role of Novel β-Lactam Agents That Target Carbapenem-Resistant Gram-Negative Organisms.定义新型针对碳青霉烯类耐药革兰氏阴性菌的β-内酰胺类药物的作用。
J Pediatric Infect Dis Soc. 2019 Jul 1;8(3):251-260. doi: 10.1093/jpids/piz002.
8
In-vitro activity of imipenem/relebactam and key β-lactam agents against Gram-negative bacilli isolated from lower respiratory tract infection samples of intensive care unit patients - SMART Surveillance United States 2015-2017.2015-2017 年美国 SMART 监测：重症监护病房下呼吸道感染患者样本中分离的革兰氏阴性杆菌对亚胺培南/雷巴他定和关键β-内酰胺类药物的体外活性。
Int J Antimicrob Agents. 2020 Jan;55(1):105841. doi: 10.1016/j.ijantimicag.2019.10.022. Epub 2019 Nov 6.
9
Relationships between antimicrobial use and antimicrobial resistance in Gram-negative bacteria causing nosocomial infections from 1991-2003 at a university hospital in Taiwan.1991年至2003年台湾某大学医院引起医院感染的革兰氏阴性菌中抗菌药物使用与抗菌药物耐药性之间的关系。
Int J Antimicrob Agents. 2005 Dec;26(6):463-72. doi: 10.1016/j.ijantimicag.2005.08.016. Epub 2005 Nov 8.
10
Activity of imipenem/relebactam against Gram-negative bacilli from global ICU and non-ICU wards: SMART 2015-2016.SMART 2015-2016 研究：亚胺培南/雷巴坦对来自全球 ICU 和非 ICU 病房的革兰氏阴性杆菌的活性。
J Glob Antimicrob Resist. 2018 Dec;15:12-19. doi: 10.1016/j.jgar.2018.05.017. Epub 2018 May 29.

引用本文的文献

1
Unveiling the role of BON domain-containing proteins in antibiotic resistance.揭示含BON结构域蛋白在抗生素耐药性中的作用。
Front Microbiol. 2025 Jan 7;15:1518045. doi: 10.3389/fmicb.2024.1518045. eCollection 2024.
2
Prevalence of difficult-to-treat resistance in ESKAPE pathogens in a third level hospital in Mexico.墨西哥一家三级医院中ESKAPE病原体的难治性耐药患病率。
Infect Prev Pract. 2024 Nov 29;7(1):100426. doi: 10.1016/j.infpip.2024.100426. eCollection 2025 Mar.
3
The prevalence of gram-negative bacteria with difficult-to-treat resistance and utilization of novel β-lactam antibiotics in the southeastern United States.
美国东南部具有难以治疗的耐药性的革兰氏阴性菌的流行情况及新型β-内酰胺类抗生素的使用情况。
Antimicrob Steward Healthc Epidemiol. 2024 Mar 18;4(1):e35. doi: 10.1017/ash.2024.26. eCollection 2024.
4
Efficacy and safety of novel carbapenem-β-lactamase inhibitor combinations: imipenem-cilastatin/relebactam results from randomized controlled trials.新型碳青霉烯类-β-内酰胺酶抑制剂组合的疗效与安全性：亚胺培南-西司他丁/瑞来巴坦随机对照试验结果
Front Med (Lausanne). 2023 Dec 21;10:1304369. doi: 10.3389/fmed.2023.1304369. eCollection 2023.
5
Comparison of the clinical characteristics and clinical outcomes of culture-positive septic shock and culture-negative septic shock among pediatric patients.比较培养阳性脓毒性休克和培养阴性脓毒性休克患儿的临床特征和临床结局。
PLoS One. 2023 Jul 14;18(7):e0288615. doi: 10.1371/journal.pone.0288615. eCollection 2023.
6
Gram-Negative Bloodstream Infection: Implications of Antimicrobial Resistance on Clinical Outcomes and Therapy.革兰阴性菌血流感染：抗菌药物耐药性对临床结局和治疗的影响
Antibiotics (Basel). 2020 Dec 18;9(12):922. doi: 10.3390/antibiotics9120922.